Evidence mapPaperPMID 34868573Full record

ReviewAnnals of medicine and surgery (2012)2021

An up to date on clinical prospects and management of osteoarthritis.

Mudasir Maqbool, Ginenus Fekadu, Xinchan Jiang, Firomsa Bekele, Tadesse Tolossa, Ebisa Turi, Getahun Fetensa, Korinan Fanta

Open access · diamondAbstract readReview
In one paragraph

Review in Annals of medicine and surgery (2012), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 73 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Mudasir MaqboolDepartment of Pharmaceutical Sciences, University of Kashmir, Hazratbal Srinagar, 190006, Jammu and Kashmir, India.
Ginenus FekaduSchool of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, N.T, Hong Kong.
Xinchan JiangSchool of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, N.T, Hong Kong.
Firomsa BekeleDepartment of Pharmacy, College of Health Science, Mettu University, Mettu, Ethiopia.
Tadesse TolossaDepartment of Public Health, Institute of Health Sciences, Wollega University, Nekemte, Ethiopia.
Ebisa TuriDepartment of Public Health, Institute of Health Sciences, Wollega University, Nekemte, Ethiopia.
Getahun FetensaSchool of Nursing and Midwifery, Institute of Health Sciences, Wollega University, Nekemte, Ethiopia.
Korinan FantaSchool of Pharmacy, Institute of Health Science, Jimma University, Jimma, Ethiopia.
Wollega University · ETChinese University of Hong Kong · HKEthiopian Civil Service University · ETJimma University · ETUniversity of Kashmir · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rising prevalence of osteoarthritis (OA) in the general population has necessitated the development of novel treatment options. It is critical to recognize the joint as a separate entity participating in degenerative processes, as well as the multifaceted nature of OA. OA is incurable because there is currently no medication that can stop or reverse cartilage or bone loss. As this point of view has attracted attention, more research is being directed toward determining how the various joint components are impacted and how they contribute to OA pathogenesis. Over the next few years, several prospective therapies focusing on inflammation, cartilage metabolism, subchondral bone remodelling, cellular senescence, and the peripheral nociceptive pathway are predicted to transform the OA therapy landscape. Stem cell therapies and the use of various biomaterials to target articular cartilage (AC) and osteochondral tissues are now being investigated in considerable detail. Currently, laboratory-made cartilage tissues are on the verge of being used in clinical settings. This review focuses on the update of clinical prospects and management of osteoarthritis, as well as future possibilities for the treatment of OA.

Indexed as

Clinical prospectsInflammatory cytokinesOsteoarthritisPain pathologyPharmacotherapy

Identifiers

PMID34868573
PMCPMC8626656
OpenAlexW3216207432

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.